Index

Note: Page numbers of article titles are in boldface type.

A
Adrenergic stress hypothesis, of takotsubo cardiomyopathy, 208
Anagrelide, takotsubo cardiomyopathy induced by, 229
Angiography, cardiac CT, in takotsubo cardiomyopathy, 258–259
coronary, in takotsubo cardiomyopathy, 129, 141–142, 179–180, 255
Angiotensin-converting enzyme inhibitor therapy, in takotsubo cardiomyopathy, 182
Anticoagulation therapy, in takotsubo cardiomyopathy, 182
Aortic aneurysms, rupture or dissection of, patterns of onset of, 149
Apical ballooning syndrome. See Takotsubo cardiomyopathy.
Arrhythmias, in takotsubo cardiomyopathy, 130, 131, 140, 141, 184

B
ß-blocker therapy, in takotsubo cardiomyopathy, 181–182, 194
Bevacizumab, and takotsubo cardiomyopathy, 238–239
Biomarker and laboratory evaluation, in takotsubo cardiomyopathy, 180
Broken heart syndrome. See Takotsubo cardiomyopathy.

C
Calcium homeostasis, in takotsubo cardiomyopathy, 198–200
Cardiac catheterization, in takotsubo cardiomyopathy, 114–115
Cardiogenic shock, in takotsubo cardiomyopathy, 183
Cardiomyopathy, stress. See Takotsubo cardiomyopathy.
takotsubo. See Takotsubo cardiomyopathy.
Cardiotoxicity, 5-fluorouracil and, 237–238
rituximab and, 236–237
Cardiovascular diseases, acute, patterns of onset of, 148–149
CD36 deficiency, and takotsubo cardiomyopathy, 214
Chemotherapy-induced takotsubo cardiomyopathy, 233–242
Chonobiology, insights of, into takotsubo cardiomyopathy, 147–156
Coagulation factors, in takotsubo cardiomyopathy, 209
Combretastatin, takotsubo cardiomyopathy induced by, 228, 239–240
Congestive heart failure, in takotsubo cardiomyopathy, 128–130

D
Drugs, inducing takotsubo cardiomyopathy, 225–231
withdrawal of, takotsubo cardiomyopathy induced by, 229

E
Endomyocardial biopsy, in takotsubo cardiomyopathy, 180
Estrogen deficiency, and takotsubo cardiomyopathy, 208
Estrogen supplementation, in takotsubo cardiomyopathy, 182–183

F
Fluorouracil, takotsubo cardiomyopathy induced by, 228
5-Fluorouracil, and cardiotoxicity, 237–238
Fragile X syndrome, and takotsubo cardiomyopathy, 211–214

G
Gadolinium, in takotsubo cardiomyopathy, 173–174

H
Heart-hand syndrome, and takotsubo cardiomyopathy, 214
Levosimendan, in takotsubo cardiomyopathy, 193, 194
Levothyroxine, takotsubo cardiomyopathy induced by, 229
Long-QT syndrome, and takotsubo cardiomyopathy, 214

Metoprolol withdrawal, takotsubo cardiomyopathy induced by, 229
Microcirculation disturbances, in takotsubo cardiomyopathy, 198–199
Mitr al regurgitation, in takotsubo cardiomyopathy, 162–163
Myocardial edema, in takotsubo cardiomyopathy, 171–173
Myocardial infarction, aborted, takotsubo cardiomyopathy in, 188
acute, patterns of onset of, 148–149

Nuclear imaging, in takotsubo cardiomyopathy, 126–127, 128, 256–258

Oxidative stress, and takotsubo cardiomyopathy, 209–210
Oxydodone withdrawal, takotsubo cardiomyopathy induced by, 233–242

Pazopanib, takotsubo cardiomyopathy induced by, 229
Polymorphisms, genetic, in takotsubo cardiomyopathy, 210–211, 212–213
Potassium chloride, takotsubo cardiomyopathy induced by, 229
Pulmonary embolism, patterns of onset of, 149

Rituximab, and cardiotoxicity, 236–237

Spasms, coronary artery and microvascular, in takotsubo cardiomyopathy, 208–209
Stress cardiomyopathy. See Takotsubo cardiomyopathy.
Stroke, patterns of onset of, 149

Takotsubo cardiomyopathy, acute presentation of, 124, 125
adrenergic stress hypothesis of, 208
algorithm for management of, 178
angrelide-induced, 229
and cancer, 236
angiotensin-converting enzyme inhibitor therapy in, 182
animal models of, 190–191
anticoagulation therapy in, 182
arrhythmias in, 130, 131, 140, 141, 184
as epinephrine specific, 190, 191, 225
atypical, 111, 192–193
ß-blocker therapy in, 181–182, 194
bevacizumab and, 238–239
biologic rhythms in, 147–148
biomarker and laboratory evaluation in, 180
biomarker profile in, 128
brain-heart interaction in, 217–223
calcium homeostasis in, 198–200
cardiomic markers in, 114, 253–259
cardiac catheterization in, 114–115
cardiac CT angiography in, 258–259
cardiogenic shock in, 183
cases in United States, 150
catecholamine-induced, 226–228
catecholamine susceptibility in, 191–192, 200–203, 225
catecholamine toxicity in, 133, 151–152, 189–193
CD36 deficiency and, 214
chemotherapy-induced, 233–242
case illustrating, 233
chronobiologic insights into, 147–156
clinical characteristics of, 112–115, 124, 125
clinical management of, 177–186
clinical presentation of, 234–235, 252–253
cogulation factors in, 209
combretastatin-induced, 228
complications of, 112, 142, 164–165, 235
congestive heart failure in, 128–130
corony angiography in, 159, 134–142, 179–180
and left ventriculography in, 255
corony artery and microvascular spasm in, 208–209
coronary microcirculation impairment in, 163–164
criteria for, 251
definition of, 208
and clinical profile of, 111–122
demographics of, 138
diagnosis of, confirmation of, 177–180
criteria for, 178
methods of, 253–259
diagnostic criteria for, 115–116, 124, 125
diagnostic imaging in, 235
differential diagnosis of, 112
Index

disease expression in, genetic determinants of, 210–211
drug-induced, 225–231
drug withdrawal-induced, 229
eye early gadolinium uptake in, 174
effects of earthquakes on, in Japan, 245
endomyocardial biopsy in, 180
epidemiology of, 138, 251–252
estrogen deficiency and, 208
estrogen supplementation in, 182–183
etiology of, 244
female sex hormones in, 203
fluorouracil-induced, 228
fragile X syndrome and, 211–214
gender discrepancy in, 142–143
gender-related differences in, 137–146
genetic heterogeneity and genetic syndromes in, 211–214
genetic polymorphisms in, 210–211, 212–213
genetics in, 207–216
heart-hand syndrome and, 214
historical aspects of, 243–244
historical pathophysiologic concepts of, 198
hospital management of, 131–132
imaging techniques in, 253–259
in aborted myocardial infarction, 188
initial reports of, 111, 123
intraventricular thrombi in, 170–171
Japanese perspective on, 243–247
laboratory findings in, 139, 140–141, 253
late gadolinium enhancement in, 173–174
left ventricular function, and ballooning pattern in, 167–168, 169
left ventricular outflow tract obstruction in, 161–162, 188–189, 198, 209
levosimendan in, 193, 194
levothyroxine-induced, 229
long-QT syndrome and, 214
LV and RV contraction patterns in, 124–126, 127
LV diastolic function in, 161
LV morphology in, 158, 159
LV systolic function in, 158–161
magnetic resonance imaging in, 115, 124, 126, 127, 130, 167–176, 180, 181, 255–256, 257
management of, 183–184

general principles of, 235
mechanisms of, 197–205, 235–236
metoprolol withdrawal-induced, 229
microcirculation disturbances in, 198–199
microvascular dysfunction in, 189
mitral regurgitation in, 162–163
morphologic alterations in, 198
multivessel vasospasm in, 189
myocardial dysfunction and, mechanisms leading to, 219
myocardial edema in, 171–173
nationwide survey of, in Japan, 244
natural history of, 123–136
nonsympathomimetic drug-induced, 228–229
nuclear imaging in, 126–127, 128, 256–258
overview of, 249–266
oxidative stress and, 209–210
oxycodone withdrawal-induced, 229
pathogenesis of, 208–210
patient care in, in Japan, 244
pazopanib-induced, 229
physical or emotional stress and, 218–219
postdischarge management of, 132
potassium chloride-induced, 229
prehospital delay in, 138, 139
presenting symptoms of, 112
prognosis in, 116–117, 197, 262
and risk of recurrence, 184
factors affecting, 220–221
recent instances of, in Japan, 245
recurrence of, 132, 142, 184
right ventricular function in, 168–170
right ventricular involvement in, 163
risk factors for, 177, 178
stressors associated with, 112, 113
studies of, 2000 to present, 260–261
susceptibility to, 219–220
symptoms of, 138–139
synonyms for, 111, 115, 177, 250
time of onset of, 150–151
transcriptional profiling in, 198
treatment of, 116, 259–262
insights from pathophysiology, 193
strategies for, 180–183
triggers of, 124, 125, 138, 139, 158, 177–178
ventricular rupture in, 184
ventricular thrombus in, 130–131
Thrombus(i), intraventricular, in takotsubo cardiomyopathy, 170–171
ventricular, in takotsubo cardiomyopathy, 130–131

V
Vascular disrupting agents, 238–240
Vascular endothelial growth factor antagonists, 238–240
Vasopasm, multivessel, in takotsubo cardiomyopathy, 189
Ventricular outflow tract, left, obstruction of, in takotsubo cardiomyopathy, 161–162, 188–189, 198, 209
Ventriculography. See also Echocardiography.
left, in takotsubo cardiomyopathy, 255